The European Affiliate of the International Alliance for Biological Standardization (IABS-EU) and the Association of European Manufacturers of Autogenous Vaccines & Sera (EMAV) have confirmed the Meeting “Autogenous Vaccines: Quality of Production and Movement in a Common Market” from the 14th to 16th of September, 2021 as a hybrid meeting at Ludwig Maximilian University in Munich, Germany.
Vaccinations in general and Autogenous vaccines in particular contribute to a global reduction of antibiotics use in livestock productions. They are essential to fill the gap wherever licensed vaccines are not available.
In the process of implementation of REGULATION (EU) 2019/6 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 11 December 2018 on veterinary medicinal products and repealing Directive 2001/82/EC members of the association of European Manufacturers of Autogenous Vaccines and Sera – EMAV - have compiled common positions for a dedicated GMP Annex for Autogenous vaccines, see https://www.emav.be/position-papers. This proposal defines future standards for the production of Autogenous vaccines to preserve their quality without hindering their manufacturing and availability.
This position paper is an invitation of EMAV to competent authorities, users and other stakeholders to define a new standard for manufacturing and for a secured use of Autogenous vaccines in the veterinary practice.
The EMAV proposal would become part of the workshop “Autogenous Vaccines: Quality of Production and Movement in a Common Market”, organised by EMAV and IABS for September as a hybrid meeting at Munich University LMU too. The results of the scientific excursus will be incorporated in a IABS – EMAV meeting report and will be shared with all participants of the workshop and all people interested in.
The meeting is intended to initiate productive conversations with manufacturers, competent authorities and users to develop a pathway to a common market which will improve overall disease control in the community, especially for diseases that suffer from a lack of conventionally-authorised products. Key items will be: GMP /GMP-like requirements, mutual recognition of inspections, import and export of Autogenous vaccines, and the relevance and impact on diagnostics when vaccinated animals are moved into areas under epidemiological surveillance.
For more information, like scientific programme, venue and accomodation in Munich, please have a look at IABS congress website.
REGISTER NOW at IABS registration file.